Comparing the effects of ketotifen fumarate eye drops and ketotifen oral pills on symptom severity and quality of life in patients with allergic rhinitis: a double-blind randomized clinical trial.
Akhavan, Asghar; Karimi-Sari, Hamidreza; Khosravi, Mohammad Hosseinet al.
2015 • In International Forum of Allergy and Rhinology, 5 (5), p. 386-91
[en] BACKGROUND: Allergic rhinitis is a chronic inflammatory disease of nasal mucosa. Previous studies have shown the therapeutic effects of ketotifen eye drops on allergic conjunctivitis and rhinitis patients. This study was designed to compare the effects of ketotifen drops and oral ketotifen pills on symptoms and quality of life in allergic rhinitis patients.
METHODS: In this double-blind randomized clinical trial, patients with mild allergic rhinitis who were referred to the allergy clinic of Baqiyatallah Hospital from March to April 2014 were randomly allocated to 2 groups; the first group received ketotifen drops (1 drop every 12 hours) with placebo pills (2 pills daily), and the second group received placebo eye drops with ketotifen pills for 4 weeks. Symptoms (sneezing, runny nose, itching, and nasal obstruction) severity were examined and Rhinitis Quality of Life Questionnaire (RQLQ) scores were evaluated in the second and fourth weeks.
RESULTS: A total of 140 patients were evaluated in 2 groups. The mean age was 30.33 years. There were no significant differences in demographic data between the groups (p > 0.05). Both groups showed a significant improvement in rhinorrhea, nasal congestion, nasal itching, coughing, sneezing, RQLQ, and nasal smear eosinophil percent compared to baseline amounts (p < 0.05). Improvements were significantly more in the drops group (p < 0.05).
CONCLUSION: Because of the absence of systemic complications in ketotifen eye drops in patients with allergic rhinitis and their easy availability in Iran, using this medication instead of systemic therapies is suggested. Nevertheless, more studies are required to evaluate the long-term effects of using this drug and the recurrence rate of symptoms.
Disciplines :
Otolaryngology
Author, co-author :
Akhavan, Asghar; Department of Otorhinolaryngology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
Karimi-Sari, Hamidreza; Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
Khosravi, Mohammad Hossein ; Université de Liège - ULiège ; Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
Arefzadeh, Esmaeil; Department of Otorhinolaryngology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
Yavarahmadi, Mohammadhosein; Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
Language :
English
Title :
Comparing the effects of ketotifen fumarate eye drops and ketotifen oral pills on symptom severity and quality of life in patients with allergic rhinitis: a double-blind randomized clinical trial.
Bousquet J, Khaltaev N, Cruz AA, et al.; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998;81:463-468.
Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28:3-9.
Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol. 2009;124:S43-S70.
Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc. 2009;30:244-254.
Schatz M, Zeiger RS, Chen W, Yang SJ, Corrao MA, Quinn VP. The burden of rhinitis in a managed care organization. Ann Allergy Asthma Immunol. 2008;101:240-247.
Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305-317.
Lagos JA, Marshall GD. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag. 2007;3:327.
Nabe M, Miyagawa H, Agrawal DK, Sugiyama H, Townley RG. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. Allergy Proc. 1991;12:267-271.
Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr Allergy Immunol. 2004;15:551-557.
Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo-and active-controlled trial. Clin Ther. 2003;25:1975-1987.
Haicl P, Cerná H. [Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis]. Cesk Slov Oftalmol. 2004;60:362-367. Czech.
van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55:116-134.
Spangler DL, Abelson MB, Ober A, Gotnes PJ. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther. 2003;25:2245-2267.
Primosch RE, Guelmann M. Comparison of drops versus spray administration of intranasal midazolam in two-and three-year-old children for dental sedation. Pediatr Dent. 2005;27:401-408.
Cumberland PM, Pathai S, Rahi JS. Prevalence of eye disease in early childhood and associated factors: findings from the millennium cohort study. Ophthalmology. 2010;117:2184-2190.e3.
Cekic O, Batman C, Yasar U, Basci NE, Bozkurt A, Kayaalp SO. Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration. Retina. 1998;18:521-525.
Illum L. Nasal drug delivery-recent developments and future prospects. J Control Release. 2012;161:254-263.
Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007;49:335-340.
Bousquet J, Heinzerling L, Bachert C, et al.; Global Allergy and Asthma European Network; Allergic Rhinitis and its Impact on Asthma. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67:18-24.
Shariat M, Pourpak Z, Khalesi M, et al. Quality of life in the Iranian adults with allergic rhinitis. Iran J Allergy Asthma Immunol. 2012;11:324-328.
Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997;117:S35-S40.
Lai DS, Lue KH, Hsieh JC, Lin KL, Lee HS. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89:589-598.
Crampton JH. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Clin Ther. 2002;24:1800-1808.
Horak F, Stuebner P, Zieglmayer R, McWhirter CL, Gekkieva M. Efficacy and safety of Ketotifen fumarate eye drops as adjunctive therapy to mometasone furoate nasal spray in subjects with seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2003;111(Suppl 1):S262.
Greiner JV, Minno G. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. Clin Ther. 2003;25:1988-2005.
Dehning D. Specific nasal allergic symptoms: differentiation in their reduction by the ocular use of ketotifen fumarate 0.025% ophthalmic solution. J Allergy Clin Immunol. 2003;111:S75.
Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin Ther. 2005;27:1392-1402.
Torkildsen GL, Abelson MB, Gomes PJ. Bioequivalence of two formulations of Ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis. Clin Ther. 2008;30:1272-1282.
Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmologica. 2009;87:549-554.
Varguez-Rodríguez M, Hernández-López A, Gómez-Dávila Rde L. Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis. Rev Med Inst Mex Seguro Soc. 2009;47:399-404.
Figus M, Fogagnolo P, Lazzeri S, et al. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. Eur J Ophthalmol. 2009;20:811-818.
Sarker S-J, Chowdhury AN, Hussain Z, Hossain AKMM, Chowdhury H. Comparison of the therapeutic efficacy of 0.1% olopatadine hydrochloride and 0.025% ketotifen fumarate in allergic conjunctivitis. Therapy. 2011;8:545-553. doi: 10.2217/thy.11.48.
Mortemousque B, Bourcier T, Khairallah M, et al.; Ketotifen Study Group. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis. J Fr Ophtalmol. 2014;37:1-8.
